Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)GlobeNewsWire • 11/15/24
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASHGlobeNewsWire • 11/13/24
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic EsophagitisGlobeNewsWire • 11/06/24
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisGlobeNewsWire • 11/06/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of InvestorsBusiness Wire • 11/04/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of InvestorsBusiness Wire • 11/04/24
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/31/24
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent SalesZacks Investment Research • 10/31/24
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 10/28/24
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAIGlobeNewsWire • 10/24/24
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAIGlobeNewsWire • 10/24/24